Lilly’s EBGLYSS reported up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis

Sanofi has recently announced their new long-term data show EBGLYSS delivered durable skin clearance and relief from persistent itch for up to four years for patients with moderate-to-severe atopic dermatitis in an open-label extension study offering once-monthly maintenance injection.

“These data underscore our unwavering commitment to expanding what people with moderate-to-severe atopic dermatitis can achieve with treatment,” said Adrienne Brown, executive vice president and president, Lilly Immunology. “For too long the focus has been around symptom management and many patients struggle to achieve consistent disease control despite cycling through topical treatments. EBGLYSS is helping transform this treatment paradigm—allowing people the opportunity to reimagine life without the frequent interruptions caused by flares or topicals applied 2-3 times per day.”

Note that EBGLYSS is an interleukin-13 inhibitor that selectively blocks IL-13 signaling with high binding affinity and slow dissociation rate. The cytokine IL-13 is a primary cytokine in atopic dermatitis, driving the type-2 inflammatory cycle in the skin, leading to skin barrier dysfunction, itch, skin thickening and infection.

The majority of patients achieved a high bar of near-complete skin clearance and significant itch relief with up to four years of continuous EBGLYSS treatment. Most patients were on EBGLYSS monotherapy, and 80% achieved results without topical corticosteroids. In addition, 80% achieved these outcomes with EBGLYSS monthly maintenance dosing during the study.

The safety in the first year of the ADlong study was consistent with the known profile in patients with moderate-to-severe atopic dermatitis, regardless of dose frequency, and no new safety signals were observed. The majority of adverse events were mild or moderate and did not lead to discontinuation.

“There is still an unmet need for people with moderate-to-severe atopic dermatitis who frequently experience unpredictable flares and are in need of treatment options that go beyond just symptomatic relief and address the underlying inflammation driving skin symptoms and persistent itch,” said Emma Guttman-Yassky, M.D., Ph.D., The Waldman Professor and Health System Chair, Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York. “These four-year findings reinforce that EBGLYSS has the potential to deliver durable disease control, helping patients flare less with or without topicals.”

---

---

Related Topics and Keywords

atopic dermatitis, Lilly's EBGLYSS, moderate-to-severe atopic dermatitis